Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AHG vs PSAI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AHG Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 5–3 Matrix Metrics)

AHG Overall Winner 6-Pillar Tally: AHG 5 – 0 PSAI (1 Tie) Matrix Metrics: AHG 5 – 3 PSAI

As of Nov 16, 2026, Akso Health Group ADS (AHG) is the stronger overall head-to-head candidate over PSAI (PSAI) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AHG carries a Unified Composite Score of 42.6/100 (HOLD) at $1.33 (N/M Forward P/E, -28.9% operating margin), whereas PSAI carries 54.8/100 (HOLD) at $29.30 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While PSAI currently prints a higher short-term Unified Composite Score (54.8/100 HOLD vs. AHG 42.6/100 HOLD), AHG captures the overall institutional head-to-head verdict (5–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-28.9% vs. N/A operating margin) and revenue trajectory (-12.9% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AHG vs PSAI
AHG NASDAQ Head-to-Head Winner
Akso Health Group ADS
Services-Business Services, Nec
$1.33
+7.26% 1D
Market Cap $1.1B
TTM Revenue $14M
Forward P/E N/M
Beta / 30D Vol 0.16β · 97% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (9.5% over 20 days), RSI 54
RSI-14: 54.2 · SMA20: $1.29 · SMA50: $1.10
PSAI US Equity
PSAI
Institutional Equity
$29.30
-0.86% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.80β · 13% Vol
Unified Composite Score
54.8 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 50.0 Mom 41.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.0% over 20 days), RSI 57
RSI-14: 56.6 · SMA20: $29.16 · SMA50: $28.39

6-Pillar Scorecard Institutional Category Breakdown (AHG 5 – 0 PSAI)

Columns: Metric · AHG · PSAI
1. Valuation Multiples AHG
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 76.8x N/M
2. Growth & Scale AHG
Revenue Growth (YoY) -12.9% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $14M N/A
Market Cap $1.1B N/A
3. Profitability & Quality AHG
Gross Margin -0.1% N/A
Operating Margin -28.9% N/A
Net Profit Margin -135.0% N/A
Return on Equity (ROE) -9.8% N/A
4. Balance Sheet & Cash Flow AHG
Cash Generation (TTM) -$1.6M EBITDA N/A
Cash Flow Margin -11.8% EBITDA Mgn N/A
Net Cash / Leverage $0.21 Book/Sh · -9.8% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat AHG
OpEx & R&D Intensity 28.8% of Rev ($4.0M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Distribution Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AHG (5) vs PSAI (3)
Institutional Metric AHG PSAI Criterion Row Edge
Market Capitalization
Scale
$1.1B N/A Larger Scale AHG
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-12.9% N/A Higher Growth AHG
Operating Margin (TTM)
Profitability
-28.9% N/A Higher Margin AHG
Net Profit Margin
Profitability
-135.0% N/A Higher Margin AHG
Return on Equity (ROE)
Capital Efficiency
-9.8% N/A Higher ROE AHG
52-Week Range Position
Momentum
36% ($1–$2) 91% ($25–$30) Stronger Trend PSAI
Beta / 30D Volatility
Risk Regime
0.16β · 97% Vol 0.80β · 13% Vol Lower Realized Risk PSAI
Unified Institutional Score
Composite Signal
42.6 / 100 (HOLD) 54.8 / 100 (HOLD) Higher Composite PSAI
Trailing 12M Revenue (USD)
Operating Scale
$14M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-0.1% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 76.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.6M EBITDA ($0.21 Book/Sh · -9.8% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PSAI +3.39 pp
AHG: -1.48% · PSAI: +1.91%
3M Horizon AHG +24.46 pp
AHG: +27.27% · PSAI: +2.81%
6M Horizon PSAI +37.13 pp
AHG: -23.12% · PSAI: +14.01%
1Y Horizon PSAI +49.41 pp
AHG: -35.12% · PSAI: +14.29%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AHG vs PSAI. Trailing 12-month operating profitability (AHG -28.9% vs PSAI N/A) and valuation multiples (AHG N/M vs PSAI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AHG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$14M
Gross Margin-0.1%
Op. Margin-28.9%
ROE / Fwd P/E-9.8% · N/M
PSAI ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AHG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AHG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PSAI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PSAI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AHG Moat Profile Cyclical / Execution-Driven Positioning
Medical Distribution Operator
Competes within the Medical Distribution value chain with $1.1B market capitalization and -28.9% operating margin.
OpEx & R&D Reinvestment 28.8% of Rev ($4.0M)
90D Engineering Disclosures 0 Published
PSAI Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AHG vs PSAI Key Questions & Quantitative Answers

As of Nov 16, 2026, Akso Health Group ADS (AHG) is the stronger overall head-to-head candidate over PSAI (PSAI) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AHG carries a Unified Composite Score of 42.6/100 (HOLD) at $1.33 (N/M Forward P/E, -28.9% operating margin), whereas PSAI carries 54.8/100 (HOLD) at $29.30 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While PSAI currently prints a higher short-term Unified Composite Score (54.8/100 HOLD vs. AHG 42.6/100 HOLD), AHG captures the overall institutional head-to-head verdict (5–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-28.9% vs. N/A operating margin) and revenue trajectory (-12.9% vs. N/A YoY).

AHG leads the Growth & Scale pillar: AHG posts -12.9% YoY revenue growth and +0.0% YoY earnings growth on $14M TTM revenue (-0.1% gross margin, -28.9% operating margin), compared with PSAI at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, AHG generates $14M in USD-normalized revenue versus N/A for PSAI. In operating R&D and SG&A reinvestment, AHG deploys 28.8% of Rev ($4.0M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PSAI.

AHG screens cheaper on headline valuation multiples. AHG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 76.8x EV/Revenue (-11.8% EBITDA margin), whereas PSAI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AHG (-9.8% ROE) versus PSAI (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, AHG carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.16β · 97% Vol realized risk). By comparison, PSAI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 13% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.